ASCO GI 2020: Dostarlimab achieved positive efficacy data in mismatch repair defect (dMMR) solid tumors

GSK recently presented the latest data from the GARNET study, which aims to assess the effectiveness of dostarlimab in treating late-stage solid tumors with mismatch repair defects (dMMR).
results showed that the objective remission rate (ORR) of patients receiving dostarimab (research-resistant PD-1 monoclonal antibody) was 38.7% (N s 106,95% CI 29.4-48.6).
, after 12.4 months of mid-level follow-up, the medium reaction duration (DoR) has not yet been reached.
Axel Hoos, Senior Vice President and Head of Oncology Research and Development at GSK, said, "We are committed to finding new ways to improve the prognostics of cancer patients who currently have limited treatment options.
ongoing GARNET study shows that dostarimab has the potential to help patients with extensive mismatch repair defects in solid tumors."
The F-queue of the GARNET trial recruited patients with dMMR solid tumors, most of whom were gastrointestinal tumors, with the highest proportion of colorectal, stomach and small intestine cancers, and most patients (n-81) with 2 or more previous systemic treatments.
patients receive 500 mg of dostarlimab every three weeks and then 1,000 mg of dostarimab (for two years) every six weeks until the disease progresses or aborts.